Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016.

Pfaller MA, Diekema DJ, Turnidge JD, Castanheira M, Jones RN.

Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S79-S94. doi: 10.1093/ofid/ofy358. eCollection 2019 Mar.

2.

Australian Group on Antimicrobial Resistance (AGAR) Australian Staphylococcus aureus Sepsis Outcome Programme (ASSOP) Annual Report 2015.

Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00016-7. Epub 2018 Dec 17.

3.

Australian Group on Antimicrobial Resistance (AGAR) Australian Enterococcal Sepsis Outcome Programme(AESOP) Annual Report 2015.

Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell (2018). 2018;42. pii: S2209-6051(18)00015-5. Epub 2018 Dec 17.

4.

Morbidity from in-hospital complications is greater than treatment failure in patients with Staphylococcus aureus bacteraemia.

Holmes NE, Robinson JO, van Hal SJ, Munckhof WJ, Athan E, Korman TM, Cheng AC, Turnidge JD, Johnson PDR, Howden BP; VANESSA study group, on behalf of the Australasian Society for Infectious Diseases (ASID) Clinical Research Network (CRN).

BMC Infect Dis. 2018 Mar 5;18(1):107. doi: 10.1186/s12879-018-3011-2.

5.

Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.

Lin YW, Zhou QT, Han ML, Chen K, Onufrak NJ, Wang J, Turnidge JD, Howden BP, Forrest A, Chan HK, Li J.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01790-17. doi: 10.1128/AAC.01790-17. Print 2018 Feb.

6.

Proposed method for estimating clinical cut-off (COCL) values: An attempt to address challenges encountered when setting clinical breakpoints for veterinary antimicrobial agents.

Turnidge JD, Martinez MN.

Vet J. 2017 Oct;228:33-37. doi: 10.1016/j.tvjl.2017.10.004. Epub 2017 Oct 16. No abstract available.

PMID:
29153105
7.

Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent.

Ogunniyi AD, Khazandi M, Stevens AJ, Sims SK, Page SW, Garg S, Venter H, Powell A, White K, Petrovski KR, Laven-Law G, Tótoli EG, Salgado HR, Pi H, Coombs GW, Shinabarger DL, Turnidge JD, Paton JC, McCluskey A, Trott DJ.

PLoS One. 2017 Sep 5;12(9):e0183457. doi: 10.1371/journal.pone.0183457. eCollection 2017.

8.

Assessing the public acceptability of proposed policy interventions to reduce the misuse of antibiotics in Australia: A report on two community juries.

Degeling C, Johnson J, Iredell J, Nguyen KA, Norris JM, Turnidge JD, Dawson A, Carter SM, Gilbert GL.

Health Expect. 2018 Feb;21(1):90-99. doi: 10.1111/hex.12589. Epub 2017 Jun 30.

9.
10.

Antimicrobial use in Australian hospitals: how much and how appropriate?

Turnidge JD, Thursky K, Chen CS, McNeil VR, Wilkinson IJ.

Med J Aust. 2016 Nov 21;205(10):S16-S20.

PMID:
27852197
11.

First detection of extended-spectrum cephalosporin- and fluoroquinolone-resistant Escherichia coli in Australian food-producing animals.

Abraham S, Jordan D, Wong HS, Johnson JR, Toleman MA, Wakeham DL, Gordon DM, Turnidge JD, Mollinger JL, Gibson JS, Trott DJ.

J Glob Antimicrob Resist. 2015 Dec;3(4):273-277. doi: 10.1016/j.jgar.2015.08.002. Epub 2015 Sep 28.

PMID:
27842872
12.

Phylogenetic diversity, antimicrobial susceptibility and virulence characteristics of phylogroup F Escherichia coli in Australia.

Vangchhia B, Abraham S, Bell JM, Collignon P, Gibson JS, Ingram PR, Johnson JR, Kennedy K, Trott DJ, Turnidge JD, Gordon DM.

Microbiology. 2016 Nov;162(11):1904-1912. doi: 10.1099/mic.0.000367. Epub 2016 Sep 22.

PMID:
27666313
13.

Australian Group on Antimicrobial Resistance Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2014.

Coombs GW, Daley DA, Thin Lee Y, Pearson JC, Robinson JO, Nimmo GR, Collignon P, Howden BP, Bell JM, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2016 Jun 30;40(2):E244-54.

14.

Australian Group on Antimicrobial Resistance Australian Enterococcal Sepsis Outcome Programme annual report, 2014.

Coombs GW, Daley DA, Thin Lee Y, Pang S, Pearson JC, Robinson JO, Johnson PD, Kotsanas D, Bell JM, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2016 Jun 30;40(2):E236-43.

15.

Australian Group on Antimicrobial Resistance Australian Enterobacteriaceae Sepsis Outcome Programme annual report, 2014.

Bell JM, Turnidge JD, Coombs GW, Daley DA, Gottlieb T, Robson J, George N.

Commun Dis Intell Q Rep. 2016 Jun 30;40(2):E229-35.

16.

Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?

Nation RL, Garonzik SM, Li J, Thamlikitkul V, Giamarellos-Bourboulis EJ, Paterson DL, Turnidge JD, Forrest A, Silveira FP.

Clin Infect Dis. 2016 Mar 1;62(5):552-558. doi: 10.1093/cid/civ964. Epub 2015 Nov 25.

17.

New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.

Cheah SE, Wang J, Nguyen VT, Turnidge JD, Li J, Nation RL.

J Antimicrob Chemother. 2015 Dec;70(12):3291-7. doi: 10.1093/jac/dkv267. Epub 2015 Aug 27.

PMID:
26318190
18.

Reviving old antibiotics.

Theuretzbacher U, Van Bambeke F, Cantón R, Giske CG, Mouton JW, Nation RL, Paul M, Turnidge JD, Kahlmeter G.

J Antimicrob Chemother. 2015 Aug;70(8):2177-81. doi: 10.1093/jac/dkv157. Epub 2015 Jun 10. Review.

PMID:
26063727
19.

Improved Synthesis of Biotinol-5'-AMP: Implications for Antibacterial Discovery.

Tieu W, Polyak SW, Paparella AS, Yap MY, Soares da Costa TP, Ng B, Wang G, Lumb R, Bell JM, Turnidge JD, Wilce MC, Booker GW, Abell AD.

ACS Med Chem Lett. 2014 Dec 11;6(2):216-20. doi: 10.1021/ml500475n. eCollection 2015 Feb 12.

20.

Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.

Jones RN, Turnidge JD, Moeck G, Arhin FF, Mendes RE.

Antimicrob Agents Chemother. 2015 Apr;59(4):2405-9. doi: 10.1128/AAC.05098-14. Epub 2015 Feb 9.

21.

Vancomycin vintage: my favourite DRESS.

Korman TM, Turnidge JD, Grayson ML.

Intern Med J. 2015 Feb;45(2):233-4. doi: 10.1111/imj.12660. No abstract available.

PMID:
25650542
22.

Enterobacteriaceae Sepsis Outcome Programme annual report, 2013.

Turnidge JD, Gottlieb T, Mitchell DH, Coombs GW, Daly DA, Bell JM; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2014 Dec 31;38(4):E327-33.

23.

Australian Enterococcal Sepsis Outcome Programme annual report, 2013.

Coombs GW, Pearson JC, Daly DA, Le TT, Robinson JO, Gottlieb T, Howden BP, Johnson PD, Bennett CM, Stinear TP, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2014 Dec 31;38(4):E320-6.

24.

Australian Staphylococcus aureus Sepsis Outcome Programme annual report, 2013.

Coombs GW, Nimmo GR, Daly DA, Le TT, Pearson JC, Tan HL, Robinson JO, Collignon PJ, McLaws ML, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2014 Dec 31;38(4):E309-19.

25.

Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Lancet Infect Dis. 2015 Feb;15(2):225-34. doi: 10.1016/S1473-3099(14)70850-3. Epub 2014 Oct 21.

PMID:
25459221
26.

Community-onset Staphylococcus aureus Surveillance Programme annual report, 2012.

Coombs GW, Daly DA, Pearson JC, Nimmo GR, Collignon PJ, McLaws ML, Robinson JO, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2014 Mar 31;38(1):E59-69.

27.

Community-onset Gram-negative Surveillance Program annual report, 2012.

Turnidge JD, Gottlieb T, Mitchell DH, Coombs GW, Daly DA, Bell JM; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2014 Mar 31;38(1):E54-8.

28.

Hospital-onset Gram-negative Surveillance Program annual report, 2011.

Turnidge JD, Gottlieb T, Mitchell DH, Coombs GW, Pearson JC, Bell JM; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2014 Mar 31;38(1):E49-53.

29.

Australian Enterococcal Sepsis Outcome Progamme, 2011.

Coombs GW, Pearson JC, Le T, Daly DA, Robinson JO, Gottlieb T, Howden BP, Johnson PD, Bennett CM, Stinear TP, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2014 Sep 30;38(3):E247-52.

30.

Prolonged growth of a clinical Staphylococcus aureus strain selects for a stable small-colony-variant cell type.

Bui LM, Hoffmann P, Turnidge JD, Zilm PS, Kidd SP.

Infect Immun. 2015 Feb;83(2):470-81. doi: 10.1128/IAI.02702-14. Epub 2014 Nov 10.

31.

The induction of Staphylococcus aureus biofilm formation or Small Colony Variants is a strain-specific response to host-generated chemical stresses.

Bui LM, Turnidge JD, Kidd SP.

Microbes Infect. 2015 Jan;17(1):77-82. doi: 10.1016/j.micinf.2014.09.009. Epub 2014 Oct 2.

PMID:
25284682
32.

Response to letter from J Mottet "Comments on the ISCAID Guidelines on the use of antimicrobial therapies in canine superficial bacterial folliculitis".

Lloyd DH, Weese JS, Blondeau JM, Boothe D, Breitschwerdt E, Guardabassi L, Papich MG, Rankin S, Turnidge JD, Sykes JE.

Vet Dermatol. 2014 Dec;25(6):567-8. doi: 10.1111/vde.12167. Epub 2014 Aug 11. No abstract available.

PMID:
25109890
33.

Genetic and molecular predictors of high vancomycin MIC in Staphylococcus aureus bacteremia isolates.

Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Coombs GW, Tan HL, Gao W, Johnson PD, Howden BP.

J Clin Microbiol. 2014 Sep;52(9):3384-93. doi: 10.1128/JCM.01320-14. Epub 2014 Jul 16.

34.

Guidelines for the diagnosis and antimicrobial therapy of canine superficial bacterial folliculitis (Antimicrobial Guidelines Working Group of the International Society for Companion Animal Infectious Diseases).

Hillier A, Lloyd DH, Weese JS, Blondeau JM, Boothe D, Breitschwerdt E, Guardabassi L, Papich MG, Rankin S, Turnidge JD, Sykes JE.

Vet Dermatol. 2014 Jun;25(3):163-e43. doi: 10.1111/vde.12118. Epub 2014 Apr 11. Review.

35.

Molecular epidemiology of enterococcal bacteremia in Australia.

Coombs GW, Pearson JC, Daley DA, Le T, Robinson OJ, Gottlieb T, Howden BP, Johnson PD, Bennett CM, Stinear TP, Turnidge JD; Australian Group on Antimicrobial Resistance.

J Clin Microbiol. 2014 Mar;52(3):897-905. doi: 10.1128/JCM.03286-13. Epub 2014 Jan 3.

36.

Consistent global approach on reporting of colistin doses to promote safe and effective use.

Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U, Tsuji BT, Turnidge JD.

Clin Infect Dis. 2014 Jan;58(1):139-41. doi: 10.1093/cid/cit680. Epub 2013 Oct 8. No abstract available.

PMID:
24107410
37.

Antimicrobial susceptibility of Staphylococcus aureus and molecular epidemiology of meticillin-resistant S. aureus isolated from Australian hospital inpatients: Report from the Australian Group on Antimicrobial Resistance 2011 Staphylococcus aureus Surveillance Programme.

Coombs GW, Pearson JC, Nimmo GR, Collignon PJ, Bell JM, McLaws ML, Christiansen KJ, Turnidge JD; Australian Group on Antimicrobial Resistance.

J Glob Antimicrob Resist. 2013 Sep;1(3):149-156. doi: 10.1016/j.jgar.2013.04.005. Epub 2013 Jun 1.

PMID:
27873625
38.

Regional resistance surveillance program results for 12 Asia-Pacific nations (2011).

Mendes RE, Mendoza M, Banga Singh KK, Castanheira M, Bell JM, Turnidge JD, Lin SS, Jones RN.

Antimicrob Agents Chemother. 2013 Nov;57(11):5721-6. doi: 10.1128/AAC.01121-13. Epub 2013 Aug 19.

39.

The urgent need for clear and accurate information on the polymyxins.

Nation RL, Li J, Turnidge JD.

Clin Infect Dis. 2013 Dec;57(11):1656-7. doi: 10.1093/cid/cit522. Epub 2013 Aug 9. No abstract available.

PMID:
23934309
40.

Vancomycin minimum inhibitory concentration, host comorbidities and mortality in Staphylococcus aureus bacteraemia.

Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, Johnson PD, Howden BP.

Clin Microbiol Infect. 2013 Dec;19(12):1163-8. doi: 10.1111/1469-0691.12168. Epub 2013 Feb 26.

41.

Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia.

Holmes NE, Turnidge JD, Munckhof WJ, Robinson JO, Korman TM, O'Sullivan MV, Anderson TL, Roberts SA, Warren SJ, Gao W, Howden BP, Johnson PD.

Antimicrob Agents Chemother. 2013 Apr;57(4):1654-63. doi: 10.1128/AAC.01485-12. Epub 2013 Jan 18.

42.

Australian Group on Antimicrobial Resistance Community-onset Gram-negative Surveillance Program annual report, 2010.

Turnidge JD, Gottlieb T, Mitchell DH, Coombs GW, Pearson JC, Bell JM; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2013 Sep 30;37(3):E219-23.

43.

Australian Group on Antimicrobial Resistance Hospital-onset Staphylococcus aureus Surveillance Programme annual report, 2011.

Coombs GW, Nimmo GR, Pearson JC, Collignon PJ, Bell JM, McLaws ML, Christiansen KJ, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2013 Sep 30;37(3):E210-8.

44.

Australian Group on Antimicrobial Resistance Enterococcus Surveillance Programme annual report, 2010.

Coombs GW, Pearson JC, Christiansen K, Gottlieb T, Bell JM, George N, Turnidge JD; Australian Group on Antimicrobial Resistance.

Commun Dis Intell Q Rep. 2013 Sep 30;37(3):E199-209.

45.

Impact of ethnicity and socio-economic status on Staphylococcus aureus bacteremia incidence and mortality: a heavy burden in Indigenous Australians.

Tong SY, van Hal SJ, Einsiedel L, Currie BJ, Turnidge JD; Australian New Zealand Cooperative on Outcomes in Staphylococcal Sepsis.

BMC Infect Dis. 2012 Oct 9;12:249. doi: 10.1186/1471-2334-12-249.

46.

Gentamicin and ototoxicity: why this drug is still in use.

Turnidge JD, Waterston JA.

Med J Aust. 2012 Jun 18;196(11):665-6. No abstract available.

PMID:
22708748
47.

Biotin analogues with antibacterial activity are potent inhibitors of biotin protein ligase.

Soares da Costa TP, Tieu W, Yap MY, Zvarec O, Bell JM, Turnidge JD, Wallace JC, Booker GW, Wilce MC, Abell AD, Polyak SW.

ACS Med Chem Lett. 2012 May 23;3(6):509-14. doi: 10.1021/ml300106p. eCollection 2012 Jun 14.

48.

Selective inhibition of biotin protein ligase from Staphylococcus aureus.

Soares da Costa TP, Tieu W, Yap MY, Pendini NR, Polyak SW, Sejer Pedersen D, Morona R, Turnidge JD, Wallace JC, Wilce MC, Booker GW, Abell AD.

J Biol Chem. 2012 May 18;287(21):17823-32. doi: 10.1074/jbc.M112.356576. Epub 2012 Mar 21.

49.

Minim typing--a rapid and low cost MLST based typing tool for Klebsiella pneumoniae.

Andersson P, Tong SY, Bell JM, Turnidge JD, Giffard PM.

PLoS One. 2012;7(3):e33530. doi: 10.1371/journal.pone.0033530. Epub 2012 Mar 12.

50.

Cross-border patients with tuberculosis.

Reynolds PN, Turnidge JD, Gottlieb T, Moore MJ; Thoracic Society of Australia and New Zealand; Australian Society for Microbiology; Australasian Society for Infectious Diseases; Public Health Association of Australia.

Med J Aust. 2011 Nov 7;195(9):523-4. No abstract available.

PMID:
22060085

Supplemental Content

Loading ...
Support Center